Estrogen and selective estrogen receptor modulators: Neuroprotection in the Women's Health Initiative era

Stephanie J. Murphy, Louise D. McCullough, Marguerite T. Littleton-Kearney, Patricia D. Hurn

Research output: Contribution to journalArticle

Abstract

Estrogen has been comprehensively studied as a neuroprotective agent in women, animals, and a variety of in vitro models of neural injury and degeneration. Most data suggest that estrogen can benefit the ischemic brain and reduce cell death. However, recent data from the Women's Health Initiative have raised concerns about the utility and safety of chronic estrogen use in women. While estrogen is a potent and reproducible neuroprotectant in animals and in vitro, its current administration in women has had unanticipated and paradoxical effects. Nonetheless, estrogen's diverse actions make it an ideal prototype for developing new neuroprotectants such as selective estrogen receptor modulators (SERMs). SERMs represent a class of drugs with mixed estrogen agonistic and antagonistic activity. Experimental and clinical data suggest a neuroprotective role for SERMs in normal and injured brain. The discrepancy among observational studies, preclinical data, and clinical trials emphasizes the need for further study of the mechanisms leading to the increased incidence of stroke observed in postmenopausal women. Research is still needed to optimize combined or estrogen alone hormone replacement therapy options as well as the prevention/management of cerebrovascular/central nervous system disorders. This review critiques estrogen and SERMs' neuroprotective potential in experimental and clinical studies of stroke and cerebrovascular disease.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalEndocrine
Volume21
Issue number1
DOIs
StatePublished - Jun 2003

Fingerprint

Selective Estrogen Receptor Modulators
Women's Health
Estrogens
Neuroprotective Agents
Stroke
Cerebrovascular Disorders
Neuroprotection
Central Nervous System Diseases
Hormone Replacement Therapy
Brain
Observational Studies
Cell Death
Clinical Trials
Safety
Incidence
Wounds and Injuries

Keywords

  • Cerebral ischemia
  • Estrogen
  • Hormone replacement therapy
  • Neuroprotection
  • Selective estrogen receptor modulators
  • Stroke

ASJC Scopus subject areas

  • Endocrinology

Cite this

Murphy, S. J., McCullough, L. D., Littleton-Kearney, M. T., & Hurn, P. D. (2003). Estrogen and selective estrogen receptor modulators: Neuroprotection in the Women's Health Initiative era. Endocrine, 21(1), 17-26. https://doi.org/10.1385/ENDO:21:1:17

Estrogen and selective estrogen receptor modulators : Neuroprotection in the Women's Health Initiative era. / Murphy, Stephanie J.; McCullough, Louise D.; Littleton-Kearney, Marguerite T.; Hurn, Patricia D.

In: Endocrine, Vol. 21, No. 1, 06.2003, p. 17-26.

Research output: Contribution to journalArticle

Murphy, SJ, McCullough, LD, Littleton-Kearney, MT & Hurn, PD 2003, 'Estrogen and selective estrogen receptor modulators: Neuroprotection in the Women's Health Initiative era', Endocrine, vol. 21, no. 1, pp. 17-26. https://doi.org/10.1385/ENDO:21:1:17
Murphy, Stephanie J. ; McCullough, Louise D. ; Littleton-Kearney, Marguerite T. ; Hurn, Patricia D. / Estrogen and selective estrogen receptor modulators : Neuroprotection in the Women's Health Initiative era. In: Endocrine. 2003 ; Vol. 21, No. 1. pp. 17-26.
@article{9c8bd47cdd55477db1027391f431a9dd,
title = "Estrogen and selective estrogen receptor modulators: Neuroprotection in the Women's Health Initiative era",
abstract = "Estrogen has been comprehensively studied as a neuroprotective agent in women, animals, and a variety of in vitro models of neural injury and degeneration. Most data suggest that estrogen can benefit the ischemic brain and reduce cell death. However, recent data from the Women's Health Initiative have raised concerns about the utility and safety of chronic estrogen use in women. While estrogen is a potent and reproducible neuroprotectant in animals and in vitro, its current administration in women has had unanticipated and paradoxical effects. Nonetheless, estrogen's diverse actions make it an ideal prototype for developing new neuroprotectants such as selective estrogen receptor modulators (SERMs). SERMs represent a class of drugs with mixed estrogen agonistic and antagonistic activity. Experimental and clinical data suggest a neuroprotective role for SERMs in normal and injured brain. The discrepancy among observational studies, preclinical data, and clinical trials emphasizes the need for further study of the mechanisms leading to the increased incidence of stroke observed in postmenopausal women. Research is still needed to optimize combined or estrogen alone hormone replacement therapy options as well as the prevention/management of cerebrovascular/central nervous system disorders. This review critiques estrogen and SERMs' neuroprotective potential in experimental and clinical studies of stroke and cerebrovascular disease.",
keywords = "Cerebral ischemia, Estrogen, Hormone replacement therapy, Neuroprotection, Selective estrogen receptor modulators, Stroke",
author = "Murphy, {Stephanie J.} and McCullough, {Louise D.} and Littleton-Kearney, {Marguerite T.} and Hurn, {Patricia D.}",
year = "2003",
month = "6",
doi = "10.1385/ENDO:21:1:17",
language = "English (US)",
volume = "21",
pages = "17--26",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Estrogen and selective estrogen receptor modulators

T2 - Neuroprotection in the Women's Health Initiative era

AU - Murphy, Stephanie J.

AU - McCullough, Louise D.

AU - Littleton-Kearney, Marguerite T.

AU - Hurn, Patricia D.

PY - 2003/6

Y1 - 2003/6

N2 - Estrogen has been comprehensively studied as a neuroprotective agent in women, animals, and a variety of in vitro models of neural injury and degeneration. Most data suggest that estrogen can benefit the ischemic brain and reduce cell death. However, recent data from the Women's Health Initiative have raised concerns about the utility and safety of chronic estrogen use in women. While estrogen is a potent and reproducible neuroprotectant in animals and in vitro, its current administration in women has had unanticipated and paradoxical effects. Nonetheless, estrogen's diverse actions make it an ideal prototype for developing new neuroprotectants such as selective estrogen receptor modulators (SERMs). SERMs represent a class of drugs with mixed estrogen agonistic and antagonistic activity. Experimental and clinical data suggest a neuroprotective role for SERMs in normal and injured brain. The discrepancy among observational studies, preclinical data, and clinical trials emphasizes the need for further study of the mechanisms leading to the increased incidence of stroke observed in postmenopausal women. Research is still needed to optimize combined or estrogen alone hormone replacement therapy options as well as the prevention/management of cerebrovascular/central nervous system disorders. This review critiques estrogen and SERMs' neuroprotective potential in experimental and clinical studies of stroke and cerebrovascular disease.

AB - Estrogen has been comprehensively studied as a neuroprotective agent in women, animals, and a variety of in vitro models of neural injury and degeneration. Most data suggest that estrogen can benefit the ischemic brain and reduce cell death. However, recent data from the Women's Health Initiative have raised concerns about the utility and safety of chronic estrogen use in women. While estrogen is a potent and reproducible neuroprotectant in animals and in vitro, its current administration in women has had unanticipated and paradoxical effects. Nonetheless, estrogen's diverse actions make it an ideal prototype for developing new neuroprotectants such as selective estrogen receptor modulators (SERMs). SERMs represent a class of drugs with mixed estrogen agonistic and antagonistic activity. Experimental and clinical data suggest a neuroprotective role for SERMs in normal and injured brain. The discrepancy among observational studies, preclinical data, and clinical trials emphasizes the need for further study of the mechanisms leading to the increased incidence of stroke observed in postmenopausal women. Research is still needed to optimize combined or estrogen alone hormone replacement therapy options as well as the prevention/management of cerebrovascular/central nervous system disorders. This review critiques estrogen and SERMs' neuroprotective potential in experimental and clinical studies of stroke and cerebrovascular disease.

KW - Cerebral ischemia

KW - Estrogen

KW - Hormone replacement therapy

KW - Neuroprotection

KW - Selective estrogen receptor modulators

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0037944237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037944237&partnerID=8YFLogxK

U2 - 10.1385/ENDO:21:1:17

DO - 10.1385/ENDO:21:1:17

M3 - Article

C2 - 12777699

AN - SCOPUS:0037944237

VL - 21

SP - 17

EP - 26

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 1

ER -